Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?
Over the past decade, a tremendous amount of consistent data have accumulated showing reduced levels of the 42 amino acid isoform of amyloid-beta (Abeta(42)) in cerebrospinal fluid (CSF) from patients with mature as well as incipient Alzheimer's disease (AD). However, as CSF analyses necessitate a spinal tap, which some consider hard to implement in the clinical routine and in clinical trials, there is a strong interest in the possible association of Abeta levels in plasma with AD. This review provides an update on the current status of research on plasma Abeta as a biomarker for AD in the context of recent patents in the field.
Zetterberg
Henrik
H
Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, The Sahlgrenska Academy at Gothenburg University, Sahlgrenska University Hospital/Mölndal, S-431 80 Mölndal, Sweden. henrik.zetterberg@gu.se
D000544:Alzheimer Disease / Q000097:blood* / Q000134:cerebrospinal fluid / Q000191:economics; D016229:Amyloid beta-Peptides / Q000097:blood* / Q000134:cerebrospinal fluid; D015415:Biomarkers; D003072:Cognition Disorders / Q000097:blood / Q000134:cerebrospinal fluid / Q000209:etiology; D006801:Humans; D010446:Peptide Fragments / Q000097:blood* / Q000134:cerebrospinal fluid
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)